A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.

Archana M Agarwal Daniel Castellano Teresa Alonso Gordoa Jose Angel Arranz Arija Emeline Colomba Gwenaëlle Gravis Loic Mourey Stephane Marie Oudard Aude Flechon Macarena González Pablo M Rey Michael Thomas Schweizer Enrique Gallardo Erica Johnston Arjun V Balar Nadine Haddad Adams K Appiah Karim Nacerddine Josep Maria Piulats

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Abemaciclib monotherapy was well tolerated and showed clinical activity in this heavily pretreated population, nearly half with visceral metastases. This study is considered preliminary proof-of-concept and designates CDK4/6 as a valid therapeutic target in prostate cancer.

Keyphrases

prostate cancer
type diabetes
insulin resistance
adipose tissue
radical prostatectomy
cell proliferation
combination therapy
double blind